Tolerability profile of SERMs.
Agnusdei
D
D
Skeletal Diseases, Eli Lilly & Co., Eli Lilly Italy, Firenze, Italy.
Iori
N
N
D000818:Animals; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D019584:Hot Flashes / Q000139:chemically induced; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects* / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use; D020246:Venous Thrombosis / Q000139:chemically induced
D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride